Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20040910 | 0.86 | IDO1 (0.44) | ARSLC22A12KIF11KCNH2IDO1 | |
| SCHEMBL22549095 | 0.84 | AR (0.41) | ARNR1H4SLC22A12KIF11KCNH2 | |
| SCHEMBL13528298 | 0.83 | CFTR (0.40) | ARNR1H4SLC22A12KIF11KCNH2 | |
| SCHEMBL1421027 | 0.83 | AR (0.50) | ARSLC22A12KIF11KCNH2IDO1 | |
| SCHEMBL19266264 | 0.81 | AR (0.36) | ARNR1H4SLC22A12KIF11KCNH2 | |
| SCHEMBL17030740 | 0.77 | NR1H4 (0.40) | ARNR1H4KIF11PDK2ALDH1A1 | |
| SCHEMBL13547902 | 0.76 | ALDH1A1 (0.59) | ARNR1H4HTTALDH1A1GAA | |
| SCHEMBL16658365 | 0.76 | KIF11 (0.51) | SLC22A12KIF11HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL8060147 | 0.75 | NR1H4 (0.60) | NR1H4HTTALDH1A1GAATDP1 | |
| SCHEMBL31099069 | 0.75 | RAPGEF4 (0.50) | KIF11KCNH2IDO1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2018-07-10 | — | — | US | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-8796277-B2 | Radioprotector compounds and related methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2014-08-05 | — | — | US | disclosed |
| US-20100022557-A1 | RADIOPROTECTOR COMPOUNDS AND RELATED METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20100022557-A1 | RADIOPROTECTOR COMPOUNDS AND RELATED METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022557-A1 | RADIOPROTECTOR COMPOUNDS AND RELATED METHODS | RAD50, ERCC2, XRCC6 | AR 1234/4885NR1H4 2317/4885SLC22A12 2969/4885 |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | IL2, IL1B, IL5 | AR 770/4885NR1H4 1209/4885SLC22A12 4340/4885 |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | IL2, IL1B, IL5 | AR 770/4885NR1H4 1209/4885SLC22A12 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.